


# VRise Therapeutics Inc. Announces Acceptance of Late Breaking Abstract for San Antonio Breast Cancer Symposium®

CAMBRIDGE, MA, UNITED STATES, November 20, 2024 / EINPresswire.com/ -- VRise
Therapeutics Inc. will be presenting groundbreaking findings at the upcoming San Antonio Breast Cancer Symposium®, set to take place on December 10-13 in San Antonio, TX 78205 USA. This yearly conference brings together leading experts in breast cancer research and treatment, offering a platform to share innovative ideas and advancements in the field.



# Late Breaking Poster:

Title: VRTX531: A Novel Best-in-Class USP1 Inhibitor for the Treatment of Triple-Negative Breast Cancer

Date: Thursday, December 12, 2024, from 12:30 PM to 2:00 PM CST.

Place: Henry B. Gonzalez Convention Center, San Antonio, TX 78205 USA.

Our research in DNA damage and repair pathway harnessed advanced AI/ML technologies to develop VRTX531, addressing the unmet needs of patients who have not responded to or have progressed beyond chemotherapy and/or PARP inhibitors. Through the integration of innovative approaches, we aim to transform patient outcomes and pioneer advancements in this evolving field," said Prashant Bhavar, Founder of VRise Therapeutics Inc.

Discovered through meticulous screening and optimization, VRTX531 is posed to emerge as a best-in-class USP1 inhibitor, with remarkable efficacy and safety both as a single agent and in combination with PARP inhibitors in-vivo. The presentation will provide valuable insights for researchers, clinicians, and industry leaders, highlighting the potential of VRTX531 in overcoming resistance to chemotherapy and PARP inhibitors, by targeting DNA damage and repair pathway. VRTX531 has been nominated for IND enabling studies and expected to advance to clinic by H2, 2025.

VRise also intends to deliver a series of presentations at the <u>AACR</u> Annual Meeting 2025, taking place from April 25 to 30, 2025, in Chicago, IL.

For more information about VRise Therapeutics Inc. and the research being presented, please visit <a href="https://www.vrisetx.com">www.vrisetx.com</a>.

## About the Symposium

The <u>San Antonio Breast Cancer Symposium (SABCS)</u> is one of the world's leading conferences focused on breast cancer research and treatment. The symposium covers a wide range of topics, including prevention, diagnosis, treatment, and survivorship related to breast cancer. It serves as a platform for presenting the latest advances in basic, translational, and clinical breast cancer research. SABCS draws over 10,000 participants from over 102 countries, fostering global networking and collaboration in the field. The program includes oncologists, radiologists, surgeons, pathologists, and other healthcare providers, ensuring a holistic approach to breast cancer care.

### About VRise Therapeutics Inc.

VRise Therapeutics is a precision oncology company aspiring to bring transformative change to the lives of cancer patients. The company is working on novel biological targets by leveraging next generation technology and a global network to accelerate the discovery and development of breakthrough drugs. For more information about VRise Therapeutics Inc., visit <a href="https://www.vrisetx.com">www.vrisetx.com</a>

# Forward Looking Statements

This press release contains forward-looking statements regarding the business of VRise Therapeutics Inc. ("VRise"). Any statement describing VRise goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of VRise current drug development pipeline, including USP1, KRAS G12C, G12D and Pan KRAS programs, is a forward-looking statement and should be considered an at-risk statement. VRise Therapeutics actual results or plans may differ materially from the anticipated results and expectations expressed in these forward-looking statements, due to various factors, including the risks and uncertainties inherent in biotech domain including drug discovery, clinical trials, drug development, and any commercialization and other risk factors identified from time to time in relation to the current line of business. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

VRise Therapeutics Inc. makes no representations as to, and no party shall be entitled to rely upon, the legal, regulatory, or tax implications of the data and or matters referred to herein, and neither VRise Therapeutics Inc. nor any of its directors, officers, employees, or agents shall incur any responsibility or liability whatsoever to any party in respect of the contents or any matters referred to in, or discussed as a result of, this presentation and/or document.

Rishi Rahangdale VRise Therapeutics Inc. +1 857-756-3370 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/762184603

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.